Heparin therapy reduces 28-day mortality in adult severe sepsis patients: A systematic review and meta-analysis

Critical Care

Volumn 18, Issue 5, 2014, Pages

  Wang, Changsong ^a   Chi, Chunjie ^a   Guo, Lei ^a   Wang, Xiaoyang ^a   Guo, Libo ^a   Sun, Jiaxiao ^b   Sun, Bo ^a   Liu, Shanshan ^a   Chang, Xuenan ^c   Li, Enyou ^a  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b First Affiliated Hospital of Quan Zhou   (China)

^c Tianjin Huanhu Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; DROTRECOGIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; ANTICOAGULANT AGENT; HEPARIN;

ARTICLE; BLEEDING; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HIGH RISK PATIENT; HUMAN; INCIDENCE; MORTALITY RATE; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEPSIS; SYSTEMATIC REVIEW; THROMBOSIS PREVENTION; TREATMENT OUTCOME; ADULT; META ANALYSIS; MORTALITY;

ADULT; ANTICOAGULANTS; HEPARIN; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEPSIS;

EID: 84988715283     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/s13054-014-0563-4     Document Type: Article

References (38)

1. Angus DC, van der Poll T: Severe sepsis and septic shock. N Engl J Med 2013, 369:840-851.
2. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R, Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup: Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013, 41:580-637.
3. Martinez JT, Fernandez G, Vazquez-Leon H: Clinical evaluation of new therapeutic concepts in septic shock. Obstet Gynecol 1966, 27:296-301.
4. Zhao C, Zhang ZD, Zhang XJ, Li X, Zhu R, Ma XC: Evaluation of clinical effects on low-dose heparin therapy for sepsis. Zhonghua Nei Ke Za Zhi 2009, 48:566-569.
5. Levi M, Levy M, Williams MD, Douglas I, Artigas A, Antonelli M, Wyncoll D, Janes J, Booth FV, Wang D, Sundin DP, Macias WL, Xigris and Prophylactic HepaRin Evaluation in Severe Sepsis (XPRESS) Study Group: Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). Am J Respir Crit Care Med 2007, 176:483-490.
6. Jaimes F, de la Rosa G: Anticoagulation and sepsis: the opportunity for a new use of heparin? Biomedica 2006, 26:150-160.
7. Zhang XJ, Ma XC: Therapeutic effects of early administration of low-dose heparin in patients with severe sepsis. Zhonghua Wai Ke Za Zhi 2006, 44:1209-1211.
8. Ai YH, Zhang LN, Gong H, Xu DM, Zhao SP, Chen JH: Clinical study of low molecular weight heparin therapy for sepsis. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2005, 17:736-739.
9. Iba T, Saito D, Wada H, Asakura H: Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: a prospective multicenter survey. Thromb Res 2012, 130:e129-e133.
10. Kirschenbaum LA, Lopez WC, Ohrum P, Tsen A, Khazin J, Astiz ME: Effect of recombinant activated protein C and low-dose heparin on neutrophil-endothelial cell interactions in septic shock. Crit Care Med 2006, 34:2207-2212.
11. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996, 17:1-12.
12. Silber S: A new and rapid scoring system to assess the scientific evidence from clinical trials. J Interv Cardiol 2006, 19:485-492.
13. Peter JV, John P, Graham PL, Moran JL, George IA, Bersten A: Corticosteroids in the prevention and treatment of acute respiratory distress syndrome (ARDS) in adults: meta-analysis. BMJ 2008, 336:1006-1009.
14. Spruance SL, Reid JE, Grace M, Samore M: Hazard ratio in clinical trials. Antimicrob Agents Chemother 2004, 48:2787-2792.
15. Moran J, Solomon P, Warn D: Methodology in meta-analysis: a study from critical care meta-analytic practice. Health Serv Outcomes Res Methodol 2004, 5:207-226.
16. Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
17. Borenstein M, Hedges LV, Higgins JPT: Fixed-effect versus random-effect models. In Introduction to Meta-Analysis. Chichester, UK: John Wiley & Sons Limited; 2009:77-85.
18. Sterne JA, Gavaghan D, Egger M: Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000, 53:1119-1129.
19. Greenland S: Quality scores are useless and potentially misleading reply to "Re: a critical look at some popular analytic methods". Am J Epidemiol 1994, 140:300-301.
20. Jüni P, Witschi A, Bloch R, Egger M: The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 1999, 282:1054-1060.
21. Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbé KA: Incorporating variations in the quality of individual randomized trials into meta-analysis. J Clin Epidemiol 1992, 45:255-265.
22. Emerson JD, Burdick E, Hoaglin DC, Mosteller F, Chalmers TC: An empirical study of thepossible relation of treatment differences to quality scores in controlled randomized clinical trials. Control Clin Trials 1990, 11:339-352.
23. Jaimes F, De La Rosa G, Morales C, Fortich F, Arango C, Aguirre D, Muñoz A: Unfractioned heparin for treatment of sepsis: a randomized clinical trial (The HETRASE Study). Crit Care Med 2009, 37:1185-1196.
24. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Pénzes I, Kübler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM, KyberSept Trial Study Group: Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001, 286:1869-1878.
25. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, Light B, Spapen H, Stone J, Seibert A, Peckelsen C, De Deyne C, Postier R, Pettilä V, Artigas A, Percell SR, Shu V, Zwingelstein C, Tobias J, Poole L, Stolzenbach JC, Creasey AA, OPTIMIST Trial Study Group: Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003, 290:238-247.
26. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr: Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709.
27. Yang CH, Guan XD, Chen J, Ouyang B, Chen MY, Li LF, Huang SW, Kou QY, Wu JF: The study of the mechanism of the effect of heparin on tissue perfusion of sepsis patients. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2008, 20:550-552.
28. Liu XL, Wang XZ, Liu XX, Hao D, Jaladat Y, Lu F, Sun T, Lv CJ: Low-dose heparin as treatment for early disseminated intravascular coagulation during sepsis: a prospective clinical study. Exp Ther Med 2014, 7:604-608.
29. Agarwal R, Gupta D: Anticoagulation in sepsis: is low-dose heparin as effective as activated protein C? Intensive Care Med 2005, 31:1297-1298.
30. Afshari A, Wetterslev J, Brok J, Møller A: Antithrombin III in critically ill patients: systematic review with meta-analysis and trial sequential analysis. BMJ 2007, 335:1248-1251.
31. Alhazzani W, Lim W, Jaeschke RZ, Murad MH, Cade J, Cook DJ: Heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review and meta-analysis of randomized trials. Crit Care Med 2013, 41:2088-2098.
32. Dhainaut JF, Shorr AF, Macias WL, Kollef MJ, Levi M, Reinhart K, Nelson DR: Dynamic evolution of coagulopathy in the first day of severe sepsis: Relationship with mortality and organ failure. Crit Care Med 2005, 33:341-348.
33. Riewald M, Ruf W: Science review: role of coagulation protease cascades in sepsis. Crit Care 2003, 7:123-129.
34. Zeerleder S, Hack CE, Wuillemin WA: Disseminated intravascular coagulation in sepsis. Chest 2005, 128:2864-2875.
35. Tyrrell DJ, Horne AP, Holme KR, Preuss JM, Page CP: Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv Pharmacol 1999, 46:151-208.
36. Cornet AD, Smit EG, Beishuizen A, Groeneveld AB: The role of heparin and allied compounds in the treatment of sepsis. Thromb Haemost 2007, 98:579-586.
37. PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group, Cook D, Meade M, Guyatt G, Walter S, Heels-Ansdell D, Warkentin TE, Zytaruk N, Crowther M, Geerts W, Cooper DJ, Vallance S, Qushmaq I, Rocha M, Berwanger O, Vlahakis NE: Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med 2011, 364:1305-1314.
38. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE: Heparin and low-molecular-weight-heparin mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy and safety. Chest 2001, 119:64-94.